A consortium of investors led a $270m funding round in Yaoshibang, a Chinese pharmaceutical trading platform. The consortium consisted of Zhejiang Pearl River Investment Management, Baidu, Green Pine Capital Partners and Guangzhou City Construction Investment. Following the investment, Yaoshibang will look to upgrade digital sales, marketing systems, and its data-sharing platform.